Erini Svokos is an associate in the firm’s Technology & Life Sciences group.

Ms. Svokos represents biotechnology, pharmaceutical, medical device, diagnostic and other life sciences companies in connection with their intellectual property, commercial and M&A transactions.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Ms. Svokos’s transactional experience includes the following strategic alliance and collaboration transactions and mergers and acquisitions:

Strategic Alliances and Collaborations

  • insitro in its strategic collaboration with Gilead to discover and develop therapies for patients with NASH, with up to $50 million in near-term payments, plus royalties and milestones
  • Obsidian Therapeutics in its strategic collaboration with Celgene to develop novel, regulated cell therapies using Obsidian’s destabilizing domain technology
  • Moderna Therapeutics in its strategic collaboration with Merck to advance novel mRNA-based personalized cancer vaccines, with an upfront payment of $200 million, and the expansion of the strategic alliance to include additional shared antigen mRNA cancer vaccines, with an equity investment of $125 million
  • ImmuNext in its exclusive, worldwide licensing agreement with Sanofi to develop and commercialize a CD40L monoclonal antibody to treat autoimmune diseases, with potential deal value of up to $500 million, plus royalties
  • Teva Pharmaceuticals in its license agreement with Heptares to develop and commercialize novel, small-molecule calcitonin gene-related peptide antagonists discovered by Heptares, valued up to $410 million, plus royalties
  • BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks
  • Blueprint Medicines in its worldwide collaboration with Roche, valued up to $1 billion with a $45 million upfront payment.
  • Surface Oncology in its collaboration with Novartis to develop next generation immunotherapies, with Surface eligible to receive up to $170 million in near term cash, plus milestones and royalties
  • Teva Pharmaceuticals, in its worldwide collaboration with Regeneron Pharmaceuticals to develop and commercialize fasinumab, with an upfront payment of $250 million, as well as ongoing research and development costs of approximately $1 billion

M&A

  • Syntimmune in its sale to Alexion, valued up to $1.2 billion, with an up-front payment of $400 million
  • Nimbus Therapeutics in the negotiation of a strategic alliance with Celgene Corporation in immunology
  • Delinia Therapeutics in its sale to Celgene, valued up to $775 million with an up-front payment of $300 million
  • Nimbus Therapeutics in connection with the $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences
  • Promedior in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $1.25 billion
Professional Experience

Ms. Svokos is a member of the American Intellectual Property Law Association.

Prior to joining Goodwin and during law school, Ms. Svokos served as the Intellectual Property Manager for BrainScope Company, Inc., a medical neuro-technology company based in Bethesda, MD.

While attending law school, Ms. Svokos served as the Symposium Editor for the Georgetown Journal of Legal Ethics and as the President of the Student Intellectual Property Law Association.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2012
Georgetown University Law Center
B.S., Chemical Engineering, 2009
Columbia University

Admissions

Bar

New Jersey
New York
U.S. Patent and Trademark Office (USPTO)
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师